Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KATALYST-AV: Ataciguat in Moderate Calcific Aortic Valve Stenosis
2025-522176-86-01Phase 3Authorised
- Sponsor
- Kardigan
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in calcific aortic stenosis (AS) comparing Ataciguat with Placebo (2 arms). Primary endpoints: Percent change in aortic valve area (AVA) and Change in peak VO2. Planned start Jun 2026; status: authorised.
02
Drugs
ataciguat
03
Conditions
calcific aortic stenosis (AS)
Beyond the preview
Go deeper on 2025-522176-86-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522176-86-01.